Valeant Pharmaceuticals Announces Management And Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St futures subdued as Nvidia results, inflation take center stage
- Oil drops to more than two-week low on hopes of Hormuz reopening
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
Valeant Pharma (VRX) Twitter Bull Throws in the Towel
February 29, 2016 1:34 PM ESTA notable Valeant Pharma (NYSE: VRX) bull on Twitter appears to be throwing in the towel.
Truth about Valeant said: "Valeant is certainly giving their best impression of a house of cards on the verge of collapse. We can no longer defend this... More
TD Securities Downgrades Valeant Pharmaceuticals (VRX) to Hold
February 29, 2016 8:19 AM ESTTD Securities downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Hold with a price target of $110.00 (from $155.00). The change follows news the company has withdrawn guidance.
"We are downgrading Valeant to HOLD from Buy to reflect the reduced visibility into F2016 outlook. The downgrade... More
Valeant Pharma (VRX) Confirms Paragraph IV Patent Challenge of Salix's Xifaxan
February 29, 2016 6:10 AM ESTValeant Pharma (NYSE: VRX) confirms that its wholly owned subsidiary, Salix Pharmaceuticals, has received a notice letter dated February 11, 2016 from Actavis Laboratories FL, Inc. (Actavis) stating that the U.S. Food and Drug Administration (FDA) has received Actavis' Abbreviated New Drug Application (ANDA) containing a... More
